Comparative efficacy and safety of oral Chinese patent medicines combined with conventional therapy for coronary heart disease complicated by diabetes: a systematic review and network meta-analysis

1

Oral Chinese patent medicines (OCPMs) are commonly used adjunctive therapies for coronary heart disease (CHD) in patients with diabetes mellitus (DM).
2

The systematic review included 71 randomized controlled trials with 7,988 patients, evaluating the efficacy and safety of OCPMs combined with conventional therapy.
3

Shexiang Baoxin Pills showed optimal efficacy in improving triglycerides, HDL-C, and cardiac function while reducing inflammatory markers.
4

Tongxinluo Capsules and Yindan Xinnaotong Soft Capsules also demonstrated significant benefits in glycemic control and cardiac function parameters.
5

The findings suggest OCPMs provide multidimensional benefits for CHD patients with DM, but caution is advised due to study heterogeneity and quality.

1